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Numerous studies have proven that both stimulation and blockade of 5-HT1A and
the blockade of 5-HT7 receptors might cause the anxiolytic-like effects. Biased
agonists selectively activate specific signaling pathways. Therefore, they might offer
novel treatment strategies. In this study, we investigated the anxiolytic-like activity,
as well as the possible mechanism of action of 1-[(2,5-dimethylphenoxy)propyl]-4-
(2-methoxyphenyl)piperazine hydrochloride (HBK-17). In our previous experiments,
HBK-17 showed high affinity for 5-HT1A and 5-HT7 receptors and antidepressant-
like properties. We performed the four plate test and the elevated plus maze test to
determine anxiolytic-like activity. Toward a better understanding of the pharmacological
properties of HBK-17 we used various functional assays to determine its intrinsic activity
at 5-HT1A, 5-HT2A, 5-HT7, and D2 receptors and UHPLC-MS/MS method to evaluate
its pharmacokinetic profile. We observed the anxiolytic-like activity of HBK-17 in both
behavioral tests and the effect was reversed by the pretreatment with WAY-100635,
which proves that 5-HT1A receptor activation was essential for the anxiolytic-like effect.
Moreover, the compound moderately antagonized D2, weakly 5-HT7 and very weakly
5-HT2A receptors. We demonstrated that HBK-17 preferentially activated ß-arrestin
signaling after binding to the 5-HT1A receptor. HBK-17 was rapidly absorbed after
intraperitoneal administration and had a half-life of about 150 min. HBK-17 slightly
penetrated the peripheral compartment and showed bioavailability of approximately
45%. The unique pharmacological profile of HBK-17 encourages further experiments
to understand its mechanism of action fully.
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INTRODUCTION
Brain serotonin participates in numerous physiological and
pathological processes. It regulates mood, sleep, or cognitive
function and modulates fear and anxiety processes. Serotonin
exerts its effects interacting with at least 14 serotonin receptor
subtypes. Among all of them, the 5-HT1A receptor plays the
most important role in the etiology of anxiety (reviewed by
Akimova et al., 2009). The 5-HT1A receptors are expressed
both presynaptically and postsynaptically. The activation of
presynaptic 5-HT1A autoreceptors, present on serotonergic
neurons in the raphe nuclei, reduces serotonergic neurons
firing and decreases serotonin levels. On the other hand, the
stimulation of postsynaptic 5-HT1A receptors, located mainly
on glutamatergic and GABAergic pyramidal neurons, modulates
serotonergic sensitivity and participates in emotional and
cognitive processes (for review see Garcia-Garcia et al., 2014).
Garcia-Garcia et al. (2014) in their review suggested that
inhibiting serotonergic neuron firing and decreasing serotonin
release, as well as reducing serotonergic signaling at postsynaptic
target receptors might result in anxiolytic-like effects. Studies
confirmed this theory, as stimulating 5-HT1A receptors in the
dorsal raphe nucleus caused an anxiolytic-like effect (Cervo
et al., 2000), whereas activating the heteroreceptors in the medial
septum and dorsal hippocampus was anxiogenic (File et al.,
1996; De Almeida et al., 1998). Collinson and Dawson (1997)
presented the anxiolytic-like effect of 5-HT1A receptor agonist,
8-OH-DPAT, which was reversed by 5-HT1A receptor antagonist
(WAY-100635). Moreover, 5-HT1A knockout mice, lacking
5-HT1A auto- and heteroreceptors, displayed a heightened
anxiety-like phenotype in several tests in rodents (Heisler et al.,
1998; Parks et al., 1998; Ramboz et al., 1998) and resistance to
benzodiazepines (Sibille et al., 2000). Overall, the above findings
demonstrate the involvement of 5-HT1A receptors in anxiogenic
processes.
The blockade of 5-HT7 receptors might also be beneficial
in anxiety. Yau et al. (2001) showed an increase in 5-HT7
receptor mRNA expression after acute, but not chronic, stress
in the rat hippocampus, which suggested the role of the
5-HT7 receptor in stress regulation. Wesołowska et al. (2006b)
demonstrated the anxiolytic-like activity of a selective 5-HT7
receptor antagonist, SB-269970, in rodent models of anxiety.
Similarly, intrahippocampal administration of the compound
induced an antianxiety-like effect in the Vogel conflict test in
rats (Wesołowska et al., 2006a). Thus, some studies suggest that
5-HT7 receptor antagonists might decrease anxiety symptoms.
Functional selectivity (also called biased signaling) is an
ability of a ligand to direct a G protein-coupled receptor toward
a conformation that activates specific signal transduction
pathway. Upon stimulation, the 5-HT1A receptor can
activate many signaling pathways, including adenylate cyclase
inhibition, extracellular signal-regulated protein kinase (ERK)
phosphorylation, G protein-coupled inwardly rectifying
potassium channel activation, voltage-gated calcium channel
inhibition, or the recruitment of ß-arrestin (Chilmonczyk
et al., 2015; Stroth et al., 2015). Newman-Tancredi et al. (2009)
presented compounds highly selective for a 5-HT1A receptor
with biased agonist profiles, i.e., F15599 or F13714. F15599
showed a marked potency for ERK1/2 phosphorylation, which
might underlie its potent antidepressant-like activity in rats.
On the other hand, F13714, which presented lower potency for
ERK1/2 phosphorylation (Newman-Tancredi, 2011), showed
an exceptionally potent antidyskinetic activity in rats (Iderberg
et al., 2015). This demonstrates that biased agonists at the
5-HT1A receptor might present different pharmacological
activity. Although it is not yet clear to what extent functional
selectivity can be exploited for therapeutic advantage, some
clinically used drugs, e.g., carvedilol (ß-blocker) show this effect
(Patel et al., 2010; Kenakin, 2011). Moreover, scientists suggest
that functional selectivity can explain the unique features of
the antipsychotic drug – aripiprazole (Mailman and Murthy,
2010). Since biased agonists preferentially activate one pathway
over others, they might offer novel treatment strategies, i.e.,
show pharmacological activity without inducing unwanted
effects. Thus, compounds with functional selectivity might show
interesting pharmacological properties in vivo and therefore are
worth investigating.
We previously demonstrated antidepressant-like activity of 1-
[(2,5-dimethylphenoxy)propyl]-4-(2-methoxyphenyl)piperazine
hydrochloride (HBK-17, Figure 1) in rodents (Waszkielewicz
et al., 2015; Kubacka et al., 2016; Pytka et al., 2016a). The
compound moderately antagonized 5-HT1A receptors expressed
in CHO-K1 cells in Ca2+ mobilization assay and showed the
affinity for 5-HT7 receptors (Waszkielewicz et al., 2015; Kubacka
et al., 2016; Pytka et al., 2016a). Since 5-HT1A and 5-HT7
receptors play a role in anxiety, we hypothesized that HBK-17
might influence anxiety-like behaviors in rodents. Therefore, our
study aimed to investigate anxiolytic-like properties in mice, as
well as the possible mechanism of action of HBK-17 using in vitro
and in vivo experiments. As knowledge of pharmacokinetics and
brain distribution of novel central-acting compounds is essential
for the proper analysis of their in vivo effects, we also evaluated
the compound’s pharmacokinetic profile.
MATERIALS AND METHODS
Animals
We used adult male Albino-Swiss mice (CD-1) weighing 18–21 g
in all experiments. The animals were kept in groups of 15 mice
in cages at room temperature of 22 ± 2◦C under light/dark
(12:12) cycle and they had free access to food (standard laboratory
FIGURE 1 | Chemical structure of HBK-17.
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pellets) and water before experiments. Humidity and ambient
temperature of the room were kept constant throughout all tests,
which were conducted between 9 a.m. and 4 p.m. The animals
were used only once in each test. All injections were given in
a volume of 10 ml/kg. Behavioral experiments were carried out
by a trained observer blind to the treatments. All experimental
procedures were approved by the I Local Ethics Committee for
Experiments on Animals of the Jagiellonian University in Krakow
(approval number 51/2015), Poland and performed under the
guidelines provided by the European Union Directive of 22
September 2010 (2010/63/EU) and Polish legislation concerning
animal experimentation.
Drugs
The tested compound 1-[(2,5-dimethylphenoxy)propyl]-4-
(2-methoxyphenyl)piperazine hydrochloride (HBK-17) was
synthesized in the Department of Bioorganic Chemistry, Chair
of Organic Chemistry, Jagiellonian University Medical College
(Figure 1; Waszkielewicz et al., 2015). HBK-17 was dissolved in
saline and administered intraperitoneally (i.p.) 30 min before
behavioral experiments. p-Chlorophenylalanine (pCPA, Sigma,
Germany) and α-methyl-p-tyrosine (AMPT, Sigma, Germany)
were suspended in 1% Tween and administered i.p. WAY-100635
(Sigma, Germany) was injected subcutaneously (s.c.) 15 min
before the studied compound.
Radioligand Binding Assays
Binding experiments were performed using membranes from
CHO-K1 cells stably transfected with the human D2 receptor
and rat cerebral cortex (α2-adrenergic and GABAA receptors).
[3H]-Methylspiperon (final concentration 0.4 nM; D2 receptor),
[3H]-clonidine (final concentration 0.2 nM; α2-adrenergic
receptor) and [3H]-muscimol (final concentration 1 nM; GABAA
receptor) were used. The final incubation mixture (total volume
250 µl) consisted of a 50 µl solution of the test compound,
50 µl of radioligand and 150 µl of diluted membranes or
the tissue suspension. The incubation was terminated by
rapid filtration over glass fiber filters GF/B (PerkinElmer,
United States) using 96-well FilterMate Harvester (PerkinElmer,
United States). Five rapid washes were performed with ice-cold
50 mM Tris–HCl buffer (pH 7.4 or 7.6). The radioactivity
was measured in MicroBeta TriLux 1450 – liquid scintillation
counter (PerkinElmer, United States). Radioligand binding data
were analyzed using iterative curve fitting routines GraphPad
Prism 5.0 (GraphPad Software). Ki values were calculated from
the Cheng and Prusoff (1973) equation. The concentrations
of analyzed compounds ranged from 10−10 to 10−5 M.
For measuring unspecific binding, clonidine – 10 µM (in
case of [3H]-clonidine) and haloperidol – 1 µM (in case
of [3H]-methylspiperon) and diazepam – 100 µM (in case
of [3H]-muscimol) were applied. At least two independent
experiments were performed for each assay.
Functional Assays
Serial dilutions were prepared in 96-well microplate in
appropriate dilution buffer (HBSS or medium) with 0.1%
BSA added, and 8–10 concentrations were tested in duplicates.
At least two independent experiments were performed for each
type of method. Assays were done according to manufacturer’s
protocols.
The level of cAMP (TRF0263, PerkinElmer assay kit) was
monitored using CHO-K1 cells with expression of the human
serotonin 5-HT1A receptor. The cells were resuspended in
stimulation buffer at 2 × 105 cells/ml. The same volume (10 µl)
of cells was added to tested compounds with 10 µM forskolin.
The antagonist response was performed using as a reference
agonist, serotonin, in EC80 (120 nM). Samples were loaded
onto a white opaque half area 96-well microplate, incubated for
40 min at room temperature. The 10 µl of reagents were added,
mixed, and incubated for 1 h. The homogeneous TR-FRET
signal was read on an EnVision Microplate Reader (PerkinElmer,
United States).
The CHO-5HT1A receptor cells were tested for
phosphorylated-ERK (p-ERK) using the SureFire ERK-
Phosphorylation AlphaLISA Assay Kit according to the
manufacturer’s instruction (ALSU-PERK-A10K, PerkinElmer).
At the experiment, cells were plated at 50,000 cells/well of 96-well
plate and grown 7 h in an incubator (5% CO2, 37◦C). The serial
dilutions of compounds were added and incubated for 15 min at
37◦C. The antagonist response was performed using serotonin as
a reference agonist at the concentration equal to EC80 (45 nM).
The “lysis buffer” (70 µl) was added and the plate gently agitated
on a plate shaker (10 min). The 10 µl of samples were transferred
to assay plates (384-OptiPlate, PerkinElmer) in duplicates and
10 µl of the reaction mix was added. The plates were incubated
for 2 h at 22◦C and measured with an EnVision a multifunction
plate reader (PerkinElmer Life Science).
The HTR1A-bla U2OS receptor cells were tested using
the Tango LiveBLAzer β-arrestin assay kit according to the
manufacturer’s instruction (K1095, Life Technologies). At the
experiment, cells were plated at 10,000 cells/well of 384-well
black, clear bottom plate and grown 12 h in an incubator
(5% CO2, 37◦C). The serial dilutions of compounds were
added and incubated for 5 h (5% CO2, 37◦). The antagonist
response was performed using serotonin as a reference agonist
at the concentration equal to EC80 (300 nM). After this
time, 8 µl of the reaction mix was added. The plates were
incubated for 2 h at 22◦C and measured with a FLUOstar
OPTIMA a multifunction plate reader (PerkinElmer Life
Science).
Behavioral Experiments
Four Plate Test
The four plate test was performed on mice according to the
method previously described (Aron et al., 1971; Bourin et al.,
2005; Pytka et al., 2016b). Mice were placed individually in the
four plate apparatus connected to the power source. After a 15 s
of habituation period, each mouse crossing from one plate to
another (two limbs on one plate, two on another) was punished
by an electric shock (0.8 mA, 0.5 s). If the mouse continued
running, it received no new shock for the following 3 s. The
number of punished crossings was calculated during the 60 s of
the test. HBK-17 was dissolved in saline and administered i.p.
30 min before the test.
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Elevated Plus Maze
The elevated plus maze was performed according to the method
previously described (Lister, 1987; Pytka et al., 2017). The
elevated plus maze for mice consisted of two opposing open
(30 cm× 5 cm), and two enclosed arms (30 cm× 5 cm× 25 cm)
connected by a central platform forming the shape of a plus sign.
The open and closed arms were connected with a central field
(5 cm× 5 cm). Each mouse was individually placed at the central
field of the apparatus with the head turned toward one of the
closed arms. Animal behavior was observed for 5 min. The device
was disinfected with 70% ethanol after each mouse. The number
of entries to open and closed arms and time spent in the open and
closed arms were measured. The experiments were recorded and
scored using aLab.io software by a trained observer blind to the
treatments. HBK-17 was dissolved in saline and administered i.p.
30 min before the test.
Spontaneous Locomotor Activity
Spontaneous locomotor activity was performed as previously
described (Pytka et al., 2015a). Photoresistor actometers (Ugo
Basile, Italy) connected to a counter for the recording of light-
beam interruptions were used to investigate the effect of the
compound on locomotor activity in mice. Locomotor activity
was counted as the number of the light-beam crossing. It was
recorded individually for each animal. After administration of
the tested compound, each mouse was placed separately in a cage
for 30 min habituation period. After that time, the parameter was
measured for 1 min and 5 min (i.e., time equal to the observation
period in four plate test and elevated plus maze test, respectively).
The cages were sanitized with 70% ethanol after each mouse.
HBK-17 was dissolved in saline and administered i.p. 30 min
before the test.
Hot Plate Test
The hot plate test was performed as described by Sałat et al.
(2015). The hot plate apparatus (Hot/Cold Plate, Bioseb, France)
consisted of an electrically heated surface and was equipped with
a temperature controller that keeps the temperature constant
at 55–56◦C. One day before the experiment, the animals were
tested for their pain sensitivity threshold (baseline latency). We
chose only mice that showed baseline latencies ≤30 s. The
latency time to pain reaction (licking hind paws or jumping) was
measured as the indicative of nociception (cutoff time – 60 s).
Animals that did not respond within 60 s were removed from
the hot plate apparatus and assigned a score of 60 s. HBK-17
was dissolved in saline and administered i.p. 30 min before the
test.
Serotonin Synthesis Blockade
To assess the involvement of the serotonergic system in the
anxiolytic-like effect of HBK-17, we used pCPA (tryptophan
hydroxylase inhibitor) as previously described (Pytka et al.,
2015b). We injected mice with pCPA at a dose of 200 mg/kg for
three consecutive days. 24 h after the last pCPA administration,
we injected mice with saline (i.p.) or HBK-17 (5 mg/kg,
i.p.). We performed the four plate test 30 min after the
administration.
Noradrenaline and Dopamine Synthesis Blockade
To investigate the involvement of the noradrenergic and
dopaminergic systems in the anxiolytic-like effect of HBK-17,
we pretreated mice i.p. with a catecholamine synthesis inhibitor,
AMPT (tyrosine hydroxylase inhibitor) at the dose of 100 mg/kg.
Control group received vehicle (1% Tween). Four hours after
AMPT or 1% Tween injection, mice were pretreated with saline
(i.p.) or HBK-17 (5 mg/kg, i.p.). We performed the four plate test
30 min after the compound administration.
Pharmacokinetic Experiments
Instrumentation and Bioanalysis
The LC/ESI-MS/MS experiments were performed on TSQ
Quantum Triple Quadrupole Mass Spectrometer (Thermo
Scientific, United States) equipped with an electrospray
ionization interface. This instrument was coupled to Dionex
3000 (Dionex, United States) ULPC system. Data acquisition and
processing were accomplished using Xcalibur data collection and
integration software. The mobile phase consisted of a mixture
of acetonitrile with an addition of 0.1% formic acid (Solvent
A) and water with an addition of 0.1% formic acid (Solvent B)
was set at a flow rate of 0.3 ml/min in gradient elution. Sample
preparations were carried out by precipitation procedure using
acetonitrile after the addition of the internal standard [IS, 2-(4-
methyl-1-piperazinyl)-4-phenylquinazoline]. The dried residue
was reconstituted in the mobile phase and injected onto an
Acclaim Polar Advantage Column (1.8 µm, 100 mm × 2.1 mm,
Dionex).
The method was validated according to validation procedures,
parameters and acceptance criteria based on USP XXIII
guidelines and FDA criterion 20/15.
Pharmacokinetic Study in Mice
All data in pharmacokinetic experiments were processed
with the pharmacokinetics software Phoenix WinNonlin
(Certara Company, United States). The non-compartmental
pharmacokinetic parameters of t1/2, MRT, AUC, Cl, and Vd were
calculated based on moment methods. First order elimination
rate constant (λz) was calculated by linear regression of time vs.
log concentration according to Eq. 1.
λz = −2.303a (1)
where a is a slope of a line.
The terminal half-life (t1/2) was calculated as:
t1/2 =
0.693
λz
(2)
The area under curve the mean plasma and tissue concentration
vs. time curve extrapolated to infinity (AUC0→∞) was estimated
using the log-linear trapezoidal rule (Eq. 3), here Cn is the
concentration of last sampling.
AUC0→∞ =
n∑
i=1
(
Ci + Ci+1
2
)
· (ti+1 − ti)+
Cn
λz
(3)
Area under the first-moment curve (AUMC0→∞) was estimated
by calculation of total area under the first-moment curve and
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extrapolated area using the Eq. 4, where tn is the time of last
sampling.
AUMC0→∞ =
n∑
i=1
(
ti · Ci + ti+1 · Ci+1
2
)
· (ti+1 − ti)
+
tn · Cn
λz
+
Cn
λ2z
(4)
Mean residence time (MRT) was calculated as:
MRT =
AUMC0→∞
AUC0→∞
(5)
Systemic clearance (Cl) was calculated as:
Cl =
Div
AUMC0→∞
(6)
Volume of distribution (Vd) was calculated as:
Vd =
Div
C0
(7)
were Div is an intravenous dose and C0 is an initial concentration.
The bioavailability (F) of the studied compound after an
intraperitoneal administration compared to the intravenous
route was calculated as:
F =
AUCi.p. · Di.v.
AUCi.v. · Di.p.
· 100% (8)
Data Analysis
Results are presented as means ± SEM. They were estimated
using one or two-way analysis of variance (ANOVA), followed
by Newman-Keuls or Bonferroni post hoc, respectively.
Differences between groups were considered as significant if
p< 0.05.
RESULTS
HBK-17 Moderately Antagonized D2 and
Weakly 5-HT7 Receptors
The radioligand binding experiments revealed that compared
with the reference compound, haloperidol, HBK-17 moderately
bound to D2 receptors. HBK-17 did not show the affinity for
α2 adrenoceptors or GABAA receptors, while the reference
drugs clonidine and diazepam strongly bound to these receptors,
respectively (Table 1).
Since HBK-17 showed a moderate affinity for D2,
5-HT2A, and 5-HT7 receptors, we investigated its intrinsic
activity toward these receptors. The results of the
functional assays showed that HBK-17 had no agonistic
properties, but it blocked dopamine D2 receptor. Its
value of the equilibrium dissociation constant for a
competitive antagonist (Kb) was 7.4-fold lower than the
Kb value of the reference antagonist – chlorpromazine
(Table 2). Similarly, HBK-17 did not show any agonistic
properties at serotonin 5-HT7 receptor but blocked the
TABLE 1 | The affinity of HBK-17 for adrenergic α2, dopaminergic D2, and
GABAergic GABAA receptors.
Compound α2 receptors
Ki ± SEM [nM]
D2 receptors
Ki ± SEM [nM]
GABAA receptors
Ki ± SEM [nM]
HBK-17 17800 ± 1.5 51.4 ± 0.7 >10000
Clonidine 2.5 ± 0.1 − −
Haloperidol − 1.1 ± 0.1 −
Diazepam − − 5.6 ± 0.7
Inhibition constants (Ki) were calculated according to the equation of Cheng and
Prusoff (1973).
receptor with Kb value 78-fold lower than the reference
antagonist, SB269970 (Table 2). As demonstrated in
Table 2 HBK-17 showed no agonistic properties and
negligible antagonistic effect at serotonin 5-HT2A receptor.
Compared with the reference compound, α-methylserotonin,
HBK-17 blocked 5-HT2A receptor 1228.1-fold weaker
(Table 2).
HBK-17 Preferentially Activated
ß-Arrestin Recruitment After Binding to
5-HT1A Receptor
A single receptor can activate numerous signaling pathways and
influence cell function oppositely. Biased agonists stabilize the
receptor’s conformation preferentially, and consequently activate
a selected signaling pathway. In our study we used cell cultures
as they provide a valuable complement to in vivo experiments,
allowing more controlled manipulation of the cellular functions
and processes.
Although 5-HT1A receptor couples to the broad panel of
second messengers, the primary coupling linkage is to the
inhibition of adenylate cyclase (Chilmonczyk et al., 2015).
Therefore, first, we evaluated the influence of HBK-17 on cAMP
production using CHO-K1 cells with expression of the human
serotonin 5-HT1A receptor. Contrary to the reference compound,
serotonin, HBK-17 did not inhibit cAMP formation. However,
the studied compound showed antagonistic properties in this
assay. HBK-17 demonstrated 6.1-fold lower Kb value compared
with the reference compound, WAY-100135 (Table 3).
To prevent over-stimulation G protein-coupled receptors
recruit cytosolic proteins – arrestins – which promote signaling
termination. Thus, we determined the influence of HBK-17 on
β-arrestin recruitment using HTR1A-bla U2OS receptor cells.
The functional studies revealed that HBK-17 relative to serotonin
moderately activated ß-arrestin recruitment in 5-HT1A receptor
(Table 3). As presented in Table 3 the efficacy of HBK-17
(Emax = 94%) was similar relative to that induced by 10 µmol L−1
serotonin (Emax = 100%), but the potency was 4.4-fold lower.
In the antagonist mode, HBK-17 did not show any effect in this
assay.
Since stimulation of 5-HT1A receptor may lead to the
activation of the ERK/MAPK pathway, we determined the effect
of HBK-17 on the level p-ERK1/2 using the CHO-5HT1A
receptor cells. The compound showed partial agonistic properties
in this assay. In the p-ERK1/2 assay, HBK-17 showed 6.6-fold
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TABLE 2 | Intrinsic activity of HBK-17 toward 5-HT2A, 5-HT7, and D2 receptors.
Receptor Treatment Agonist mode∗ Antagonist mode∗∗
Emax % SEM pEC50 Emax % SEM pIC50 Kb [nM] R2 Kb
5-HT7 Serotonin 100% 3.5 8.34 1% 7.0 n.c. n.c. n.c.
SB269970 4% 3.5 n.c. 8% 0.0 8.82 0.5 0.993
HBK-17 18% 1.5 n.c. 11% 0.0 6.91 39 0.919
5-HT2A α-Methylserotonin 100% 0.0 8.70 1% 0.0 n.c. n.c. n.c.
Pimavanserin 1% 0.5 n.c. 0% 0.0 8.04 0.57 0.948
HBK-17 1% 0.0 n.c. 58% 3.0 4.95 700 0.932
D2 Apomorphine 100% 2.0 7.89 1% 0.5 n.c. n.c. n.c.
Chlorpromazine 5% 2.5 n.c. 1% 0.0 8.53 0.89 0.956
HBK-17 2% 0.0 n.c. 0% 0.0 7.65 6.63 0.881
Emax, the maximum possible effect; pEC50, the negative logarithm of concentration of compound where 50% of its maximal effect was observed; pIC50, the negative
logarithm of concentration of a compound where 50% of its maximal inhibitory effect was observed; Kb, the equilibrium dissociation constant for a competitive antagonist
determined using of the Cheng-Prusoff equation; n.c., not calculable. ∗Results were normalized as percentage of maximal agonist response (5-HT2A, α-methylserotonin
10−6 M; 5-HT7, serotonin 10−6 M; D2 receptors, apomorphine 10−6 M). ∗∗Results were normalized as percentage of maximal response in the absence of antagonist.
TABLE 3 | Intrinsic activity of HBK-17 at 5-HT1A receptor in various functional assays.
5-HT1A assay Treatment Agonist mode∗ Antagonist mode∗∗
Emax % SEM pEC50 Emax % SEM pIC50 Kb [nM] R2 Kb
cAMP Serotonin 100 2.0 7.52 4 0.5 n.c. n.c. n.c.
WAY-100135 2 0.5 n.c. 8 1.0 7.9 6.4 0.939
HBK-17 1 1.5 n.c. 4 1.0 6.8 39 0.894
ß-arrestin Serotonin 100 0.5 7.13 2 1.0 n.c n.c. n.c.
WAY-100135 1 0.5 n.c. 5 0.9 8.1 5.9 0.779
HBK-17 94 0.5 6.49 29 3.0 n.c. n.c. n.c.
pERK1/2 Serotonin 100 5.0 7.95 1 0.5 n.c n.c. n.c.
WAY-100135 2 1 n.c. 0 0.0 7.90 2.7 0.769
HBK-17 40 1.5 7.85 35 0.9 6.7 29 0.836
Ca2+ Serotonin 100a 1.0a 6.50a 1 0.0 n.c.a n.c.a n.c.a
WAY-100135 2 0 n.c. 0 0.0 8.3 0.8 0.997
HBK-17 1a 0.0a n.ca 4a 0.0a 8a 6.9a 0.907a
Emax, the maximum possible effect; pEC50, the negative logarithm of concentration of compound where 50% of its maximal effect was observed; pIC50, the negative
logarithm of concentration of a compound where 50% of its maximal inhibitory effect was observed; Kb, the equilibrium dissociation constant for a competitive antagonist
determined using of the Cheng-Prusoff equation; n.c., not calculable. ∗Results were normalized as percentage of maximal agonist response (serotonin 10−6 M). ∗∗Results
were normalized as percentage of maximal response in the absence of antagonist. aKubacka et al. (2016).
higher potency than serotonin, but 2.5-fold lower efficacy
(Table 3). In the antagonist mode HBK-17, compared with the
reference antagonist, WAY-100135, showed 10.7-fold lower Kb
value.
Our previous studies demonstrated that in the Ca2+
mobilization assay the reference compound, WAY-100135,
showed strong antagonistic properties (Table 3; Kubacka et al.,
2016).
HBK-17 Increased the Number of
Punished Crossings in the Four Plate
Test and Did Not Affect the Pain
Response in the Hot Plate Test in Mice
In order to evaluate the anxiolytic-like properties of the
compound, we performed four plate test in mice. The tested
compound HBK-17 at a dose 5 mg/kg (but not 1.25, 2.5,
10, or 20 mg/kg) significantly increased the number of
punished crossings by 70.9% compared with non-treated control
[F(5,54) = 3.791, p < 0.01] (Figure 2A). A reference 5-HT1A
receptor agonist, 8-OD-DPAT, at a dose 0.5 mg/kg (but not
0.25, 1 or 2 mg/kg) significantly increased the number of
punished crossings by 38.2% [F(4,37) = 3.791, p < 0.05]
(Figure 2C). Another reference compound SB269970, a 5-HT7
receptor antagonist, at a dose 2.5 mg/kg (but not 1.25 or
5 mg/kg) increased the number of punished crossings by
137.5% compared with non-treated control [F(3,29) = 5.903,
p < 0.01] (Figure 2D). Compounds with analgesic properties
might show false positive results in the four plate test.
Therefore, we evaluated the HBK-17 influence on pain
responses in the hot plate test in mice. HBK-17 at doses
1.25–20 mg/kg did not increase the latency time to the first
hind paw or/and jumping response [F(5,54) = 0.466, ns]
(Figure 2B).
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FIGURE 2 | The effect of HBK-17 (A), 8-OH-DPAT (C), and SB 269970 (D) on the behavior of mice in the four plate test and the influence of HBK-17 on the pain
threshold (B). HBK-17 and SB 269970 were administered intraperitoneally 30 min before the experiment, whereas 8-OH-DPAT was injected 15 min before the four
plate test. CONT – control group; Statistical analysis: one-way ANOVA (Newman-Keuls post hoc) ∗p < 0.05, ∗∗p < 0.01 vs. control group; n = 8–10 mice per group.
HBK-17 Increased the Time in the Open
Arms and Open Arm Entries in the
Elevated Plus Maze Test in Mice
To confirm our findings, we performed another experiment
assessing anxiolytic-like properties of the compound, i.e.,
elevated plus maze test. HBK-17 at a dose 5 mg/kg (but
not 1.25, 2.5, 10, or 20 mg/kg) compared with non-treated
control significantly increased the time spent in the open
arms by 38.9% [F(5,54) = 4.143, p < 0.01] and the number
of open arm entries by 28.6% [F(5,54) = 5.267, p < 0.01]
(Figures 3A,B). 8-OH-DPAT at a dose 2 mg/kg (but not
0.25, 0.5 or 1 mg/kg) compared with non-treated control
significantly increased the time spent in the open arms by
154.3% [F(3,29) = 3.710, p < 0.05] but had no effect on the
number of open arm entries [F(3,29) = 2.224, ns] (Figures 3C,D).
SB269970 at a dose 2.5 mg/kg (but not 1.25 or 5 mg/kg)
compared with non-treated control significantly increased the
time spent in the open arms by 76.4% [F(3,28) = 3.026,
p < 0.05] and the number of open arm entries by 48.6%
[F(3,30) = 3.396, p < 0.05] (Figures 3E,F). Diazepam at the
doses 1.25 and 2.5 mg/kg (but not 0.3125 or 0.625 mg/kg)
compared with non-treated control significantly increased the
time spent in the open arms by 84.6 and 59.9% [F(4,35) = 12.870,
p < 0.0001], respectively. The reference compound significantly
increased the number of open arm entries at the doses
0.625, 1.25, and 2.5 mg/kg (but not 0.3125 mg/kg) by 78.5,
73.9, and 124.6% [F(4,35) = 5.908, p < 0.01], respectively
(Figures 3G,H).
No Effect of HBK-17 After Pretreatment
With pCPA or WAY-100635, But Not
AMPT, in the Four Plate Test in Mice
To find the possible mechanism of anxiolytic-like activity of
HBK-17, we again performed the four plate test, but this
time using tryptophan hydroxylase inhibitor (pCPA), tyrosine
hydroxylase inhibitor (AMPT), and 5-HT1A receptor antagonist
(WAY-100635), which would show the involvement of the
serotonergic system, noradrenergic system, and the 5-HT1A
receptor, respectively. HBK-17 (5 mg/kg) significantly increased
number of punished crossings of mice by 84.2% compared with
non-treated control group. Three days treatment with pCPA
(200 mg/kg) did not influence the measured parameter but
abolished the activity of HBK-17 (Figure 4A). The two-way
ANOVA demonstrated no effect of pCPA [F(1,28) = 0.887; ns],
significant effect of HBK-17 [F(1,28) = 7.986; p < 0.01], and
significant interaction [F(1,28) = 4.831; p < 0.05]. Similarly, the
administration of HBK-17 (5 mg/kg) increased the number of
punished crossings by 60.0% compared with non-treated control
group. Pretreatment with WAY-100635 (0.3 mg/kg) did not
influence the number of punished crossings, but it antagonized
the effect of HBK-17 (Figure 4B). The two-way ANOVA
demonstrated no effect of WAY-100635 [F(1,28) = 3.092; ns],
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FIGURE 3 | The effect of HBK-17 (A,B), 8-OH-DPAT (C,D), SB 269970 (E,F), or diazepam (G,H) on the behavior of mice in the elevated plus maze test. HBK-17,
SB 269970, and diazepam were administered intraperitoneally 30 min before the test, whereas 8-OH-DPAT was injected 15 min before the elevated plus maze test.
CONT. CONT – control group; Statistical analysis: one-way ANOVA (Newman-Keuls post hoc) ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. control group; n = 8–10 mice
per group.
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FIGURE 4 | The effect of p-chlorophenylalanine [pCPA, (A)], WAY-100635 (B), or α-methylphenylalanine [AMPT, (C)] on anxiolytic-like activity of HBK-17 in the four
plate test in mice. pCPA was injected intraperitoneally (i.p.) once daily for three consecutive days. Twenty-four hour after the last injection and 30 min before the test
mice received (i.p.) either HBK-17 or 0.9% NaCl. WAY-100635 was administered subcutaneously 15 min before HBK-17. AMPT was injected (i.p.) 4 h before
HBK-17. Vehicle-treated groups received 1% Tween (i.p.). Statistical analysis: two-way ANOVA (Bonferroni post hoc); ∗p < 0.05, ∗∗p < 0.01 vs. respective control
group receiving 1% Tween; #p < 0.05, ##p < 0.01 vs. respective group receiving HBK-17 at the dose 5 mg/kg; n = 8 mice per group.
significant effect of HBK-17 [F(1,28) = 4.209; p < 0.05], and
significant interaction [F(1,28) = 8.589; p < 0.01]. The injection
of HBK-17 (5 mg/kg) caused a significant increase by 76% in
the number punished crossings, while AMPT (100 mg/kg) had
no effect on this parameter. Pretreatment with AMPT did not
influence the effect of HBK-17 (Figure 4C) in this test. The
two-way ANOVA showed no effect of AMPT [F(1,28) = 0.209;
ns], significant effect of HBK-17 [F(1,28) = 28.490; p< 0.05], and
no significant interaction [F(1,28) = 0.209; ns].
Neither HBK-17 Alone nor
Co-Administered With pCPA, AMPT or
WAY-100635 Affected Locomotor Activity
in Mice
To investigate whether the observed increased number of
punished crossings was not due to psychostimulant properties,
we evaluated the effect of HBK-17 on locomotor activity of
mice in the 1-min session. The compound did not influence
the locomotor activity of mice at the doses 1.25–20 mg/kg
during the 1-min session [F(5,42) = 2.616; ns] (Table 4). To
exclude false positive results in the elevated plus maze test, we
also evaluated the effect of HBK-17 on locomotor activity of
mice in 5-min session. The compound did not influence the
locomotor activity of mice at the doses 1.25–20 mg/kg during the
5-min session [F(5,42) = 2.485; ns] (Table 4). Neither HBK-17
alone nor in combinations with pCPA or AMPT influenced the
locomotor activity of mice (Table 4). The two-way ANOVA
demonstrated no effect of pCPA [F(1,28) = 0.405; ns], no
effect of HBK-17 [F(1,28) = 0.192; ns], and no significant
interaction [F(1,28) = 1.001; ns]. In case of AMPT the two-way
ANOVA showed no effect of AMPT [F(1,28) = 0; ns], no
effect of HBK-17 [F(1,28) = 0.026; ns], and no significant
interaction [F(1,28) = 1.224; ns]. The administration of HBK-17,
WAY-100635 or the combination of both, did not affect the
locomotor activity of mice (Table 4). The two-way ANOVA
demonstrated no effect of WAY-100635 [F(1,28) = 1.452; ns],
no effect of HBK-17 [F(1,28) = 0.088; ns], and no significant
interaction [F(1,28) = 1.316; ns].
Pharmacokinetic Study and
Bioavailability
We used a well-validated UPLC-MS/MS method to determine
pharmacokinetic parameters after i.v. and i.p. administration
of HBK-17 at a dose of 5 mg/kg in mice. The parameters
for the compound are presented in Table 5. HBK-17 was
eliminated rather fast (i.v.: t1/2 = 105 min; i.p.: t1/2 = 150 min).
The absorption of the compound after i.p. administration
was also fast (tmax = 5 min) with the maximum plasma
concentration at 806.7 ng/mL. The volume of distribution
was 9.7 L/kg, suggesting the distribution of the compound
throughout the total body water. The absolute bioavailability
after i.p. administration, which was estimated based on the
AUC0→∞ calculated from zero time to infinity, was significant
(F = 44.8%).
HBK-17 distributed widely and rapidly in the brain within the
time course examined. Thus, we can conclude that the compound
penetrated the blood-brain barrier. We detected the highest
concentrations of HBK-17 5 min after i.p. administration. The
compound’s concentration in the brain decreased significantly
within 8 h, which suggests that HBK-17 not tend to accumulate.
The AUC ratio between brain and plasma was 1.13 and
0.96 after i.v. or i.p. administration revealed a satisfactory
binding affinity to mice brain. The other parameters were as
follows: AUC0→∞ = 23860 ng . min/g, MRT = 147.1 min,
Cmax = 523.8 ng/g, tmax = 5 min.
DISCUSSION
We found that HBK-17 possessed anxiolytic-like activity in
mice, which depended on the 5-HT1A receptor activation. After
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TABLE 4 | The influence of HBK-17 and its combinations with pCPA, AMPT, or
WAY-100635 on locomotor activity of mice.
Treatment Dose [mg/kg] Number of crossings ± SEM
Vehicle − 36.0 ± 8.3
1.25 32.6 ± 4.7
HBK-17 2.5 35.6 ± 6.6
(1-min session) 5 44.8 ± 8.4
10 59.3 ± 6.4
20 31.3 ± 3.2
Vehicle − 323.4 ± 53.7
1.25 295.6 ± 20.4
HBK-17 2.5 326.1 ± 19.5
(5-min session) 5 317.0 ± 24.5
10 289.9 ± 19.5
20 204.8 ± 19.1
Vehicle − 41.8 ± 9.9
HBK-17 5 30.9 ± 7.6
pCPA 200 29.4 ± 6.8
HBK-17 + pCPA 5 + 200 33.6 ± 5.0
Vehicle − 33.1 ± 7.1
HBK-17 5 23.3 ± 3.9
AMPT 100 24.5 ± 7.3
HBK-17 + AMPT 5 + 100 31.9 ± 8.5
Vehicle − 48.3 ± 5.9
HBK-17 5 41.1 ± 9.9
WAY-100635 0.3 27.9 ± 7.8
HBK-17 + WAY-100635 5 + 0.3 40.4 ± 9.9
HBK-17 was administered intraperitoneally (i.p.) 30 min before the test. pCPA
was injected intraperitoneally (i.p.) once daily for three consecutive days.
Twenty-four hour after the last injection and 30 min before the test mice
received (i.p.) either HBK-17 or 0.9% NaCl. WAY-100635 was administered
subcutaneously 15 min before HBK-17. AMPT was injected (i.p.) 4 h before
HBK-17. Vehicle-treated groups received 0.9% NaCl (i.p.). Statistical analysis:
one-way ANOVA (Newman-Keuls post hoc; in case of HBK-17 administered alone)
or two-way ANOVA (Bonferroni post hoc; in case of combined treatments); n = 8
mice per group.
binding to the 5-HT1A receptor, the compound preferentially
activated β-arrestin recruitment over Ca2+ mobilization,
phosphorylation of ERK1/2 or cAMP formation inhibition.
We also demonstrated that following a single i.v. or i.p.
administration, HBK-17 showed relatively high bioavailability,
rapid absorption to the blood but rather low distribution to the
brain.
Serotonin 5-HT1A and 5-HT7 receptors play a role in anxiety
(Żmudzka et al., 2018). Studies proved that both stimulation and
blockade of 5-HT1A and the blockade of 5-HT7 receptors might
cause anxiolytic-like effects (Garcia-Garcia et al., 2014; Nikiforuk,
2015). Since HBK-17 showed affinity for both 5-HT1A and 5-HT7
receptors, it might also influence anxiety-like behaviors. Thus,
as the first step of our studies, we investigated the compound’s
anxiolytic-like properties using a preliminary assay based on
the unconditioned fear model of anxiety, i.e., the four plate
test in mice. Our results show that the compound possessed
significant anxiolytic-like activity at one dose tested (5 mg/kg).
Since HBK-17 did not influence pain responses and locomotor
activity of mice, we can conclude that the obtained results were
specific to anxiety.
TABLE 5 | Pharmacokinetic parameters for HBK-17 after i.v. and i.p
administration at a dose of 5 mg/kg to mice.
Parameters
i.v. i.p.
C0 [ng/mL] 1482 −
AUC0→∞ [ng . min/mL] 55558 24877
MRT [min] 107.9 101.4
t0.5 [min] 105.4 149.9
Cmax [ng/mL] − 806.7
tmax [min] − 5
Vd [L/kg] 13683.6 −
Cl [L/min/kg] 90 −
F [%] 44.8
C0, the initial concentration; Cmax, the maximum plasma concentration; tmax, time
to reach the maximum plasma concentration; t1/2, terminal half-life; MRT, mean
residence time; AUC0→∞, area under the concentration-time curve from zero up
to infinitive time; Cl, systemic clearance; Vd, volume of distribution; F, bioavailability.
Next, we decided to confirm our findings in another
experiment, i.e., the elevated plus maze, which uses a natural
aversion of rodents for open and elevated areas. Compounds with
anxiolytic-like properties increase the time spent and the number
of entries to the open arms of the elevated plus maze. Similarly,
the administration of HBK-17 at only one dose (5 mg/kg)
increased the time spent and the number of entries in the open
arms of the elevated plus maze. The compound did not affect
the locomotor activity of mice; thus, the observed effect could
not be attributed to psychostimulant properties. In our previous
experiments, HBK-17 showed strong antiarrhythmic properties
in adrenaline-induced arrhythmia in rats (Pytka et al., 2016a).
Anxiety disorder patients often report autonomic manifestations
of anxiety, such as increased heart rate or blood pressure
(Gałuszka, 2013). These factors also determine anxiety levels in
animals (Pattij, 2002). The fact that HBK-17 normalized heart
rhythm in adrenaline-induced arrhythmia might complement its
anxiolytic-like effect.
Interestingly, in both behavioral tests, HBK-17 showed an
inverted U-shaped dose-effect (only one dose was active).
A similar dose-effect function was demonstrated for a reference
compound, a selective 5-HT7 receptor antagonist, SB 269970
and a 5-HT1A receptor agonist, 8-OH-DPAT in the four plate
test. In the elevated plus maze test the only active dose
of 8-OH-DPAT was the highest dose tested (i.e., 2 mg/kg).
Conversely, a well-known anxiolytic, diazepam, showed a dose
dependent-effect in both tests (Pytka et al., 2015a). Although
scientists very often report such a non-linear relationship in
pharmacological studies (Baldi and Bucherelli, 2005), an inverted
U-shaped dose-effect it is very poorly understood. Some scientists
suggest that this effect might have multifactorial nature, which
is difficult to explain. In the case of HBK-17, there might
be an explanation of this phenomenon. The anxiolytic-like
effect of HBK-17 at higher doses might disappear due to the
sedative properties of the compound, which we reported in
our previous studies (ED50 = 15.0 mg/kg, observation time:
30 min) (Waszkielewicz et al., 2015). It is also possible that
as HBK-17, 8-OH-DPAT, and SB 269970 showed an inverted
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U-shaped dose-effect, this might be a common feature of
serotonin agents.
Toward a better understanding of the pharmacological
properties of HBK-17, we evaluated the compound’s affinity
for GABAA, adrenergic α2 and dopamine D2 receptors. The
studied compound showed a moderate affinity for D2 receptors,
whereas no affinity for GABAA and α2 receptors. Our previous
studies demonstrated that HBK-17 showed high affinity for α1
(Pytka et al., 2016a) and 5-HT7 (Waszkielewicz et al., 2015),
moderate for 5-HT2A (Kubacka et al., 2016), and very low for
5-HT6 and 5-HT3 receptors (Waszkielewicz et al., 2015; Kubacka
et al., 2016). Bearing that in mind, we evaluated the compound’s
intrinsic activity at 5-HT2A, 5-HT7, and D2 receptors. Our
functional studies indicated that HBK-17 was a moderate D2 and
very weak 5-HT7 receptors antagonist.
In our previous experiments, HBK-17 showed antagonistic
properties at 5-HT1A receptor (Ca2+ mobilization assay),
in this study we demonstrated that the compound showed
functional selectivity at the 5-HT1A receptor. It preferentially
activated ß-arrestin recruitment vs. p-ERK1/2, cAMP production
inhibition or Ca2+ mobilization. Interestingly, HBK-17 showed
partial agonistic activity in the p-ERK1/2 assay. Studies
demonstrated decreased ERK expression and phosphorylation
in post-mortem brains of depressed patients (suicide victims)
(Dwivedi et al., 2001). Similar changes were observed in animal
models of depression (Tiraboschi et al., 2004). Therefore, the
fact that HBK-17 increased p-ERK1/2 might at least in part
underlie its previously described antidepressant-like properties
(Waszkielewicz et al., 2015; Kubacka et al., 2016). At this point,
it is also worth mentioning that ß-arrestins desensitize not
only G-protein-dependent signal pathways but also promote
novel pathways of signal transduction, e.g., ERK, JNK, p38,
or Akt (for review see DeWire et al., 2007). Thus, it might
be possible that the observed increase in p-ERK1/2 might
also be a result of the activation of ß-arrestin recruitment.
Nevertheless, we need to perform more experiments to explain
this issue.
To find the possible mechanism of anxiolytic-like activity
of HBK-17, we performed another set of experiments, i.e.,
pretreated mice with pCPA (tryptophan hydroxylase inhibitor),
WAY-100635 (non-selective 5-HT1A receptor antagonist), or
AMPT (tyrosine hydroxylase inhibitor). Imaizumi et al. (1996)
demonstrated that a 3-day treatment with pCPA (200 mg/kg)
significantly reduced serotonin levels in the cortex (30%),
diencephalon (35%), midbrain (24%), and pons with medulla
(34%). The depletion of serotonin levels by pCPA abolished the
anxiolytic-like activity of HBK-17 in the four plate test. We
observed a similar effect after pretreatment with WAY-100635,
which implies that the anxiolytic-like activity of HBK-17
depended on the activation of the serotonergic system, and
particularly 5-HT1A receptors. In contrast, AMPT did not
affect the compound’s activity in this test. This suggests that
noradrenergic and dopaminergic systems are not involved
in HBK-17 anxiolytic-like activity. We speculate that the
anxiolytic-like activity of HBK-17 might have been a result
of the postsynaptic 5-HT1A receptors internalization induced
by the recruitment of ß-arrestins and possibly the stimulation
of presynaptic receptors. Nonetheless, our hypothesis requires
confirmation.
Pharmacokinetic parameters of the compound influence
its pharmacological activity. Thus, we evaluated the
pharmacokinetic profile of HBK-17. We demonstrated that
HBK-17 was rapidly absorbed with the peak concentration
occurring after 5 min and had a rather long half-life of about
105 and 150 min when administered i.v. or i.p., respectively. The
volume of distribution (9.7 L/kg) suggests that the compound was
moving throughout the body water. We should emphasize the
relatively high bioavailability (44.8%) of the studied compound.
HBK-17 could penetrate the brain tissue with the brain/plasma
ratio of 1.13 and 0.96 after i.v. or i.p. administration, respectively.
The results show that we could administer the compound by
both i.v. and i.p. routes. Therefore, we conclude that HBK-17 has
a desirable pharmacokinetic profile for pharmacological studies.
Moreover, to our knowledge, this is the first report to quantify
HBK-17 in biomatrices and assess its pharmacokinetics in mice.
CONCLUSION
We demonstrated that HBK-17 possessed anxiolytic-like activity
in mice, which depended on the 5-HT1A receptor activation. The
compound after binding to the 5-HT1A receptor preferentially
activated β-arrestin recruitment over Ca2+ mobilization,
phosphorylation of ERK1/2 or cAMP formation inhibition.
We also demonstrated that following a single i.v. or i.p.
administration, HBK-17 showed relatively high bioavailability,
rapid absorption to the blood but rather low distribution to brain.
The interesting pharmacological profile of HBK-17 encourages
further experiments to understand its mechanism of action fully.
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Waszkielewicz and Marona. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 13 October 2018 | Volume 9 | Article 1146
